NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7…
Read More...
Read More...
